Yasheng Zhu1, Shancheng Ren1, Taile Jing1, Xiaobing Cai2, Yawei Liu2, Fubo Wang1, Wei Zhang1, Xiaolei Shi1, Rui Chen1, Jian Shen3, Ji Lu1, Chuanliang Xu1, Huiqing Wang1, Haifeng Wang1, Yang Wang4, Bing Liu1, Yaoming Li1, Ziyu Fang1, Fei Guo1, Meng Qiao1, Dan Shen1, Xin Lu1, Xu Gao1, Jianguo Hou1, Yinghao Sun5. 1. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, P.R. China. 2. Health Division of Guard Bureau, General Staff Department of Chinese People׳s Liberation Army, Beijing, P.R. China. 3. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, P.R. China; Department of Urology, Changshu No. 2 Pepople׳s Hospital, Changshu, Jiangsu Province, P.R. China. 4. Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, P.R. China. 5. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, P.R. China. Electronic address: sunyh@medmail.com.cn.
Abstract
OBJECTIVE: In recent years, great effort has been made to explore new biomarkers for early detection of prostate cancer. Our previous study has demonstrated the high prevalence of TTTY15-USP9Y in prostate cancer samples from a Chinese population. Our aim was to evaluate the clinical utility of TTTY15-USP9Y in predicting the prostate biopsy outcome. MATERIALS AND METHODS: We retrospectively examined the expression of TTTY15-USP9Y in 226 qualified urine sediment samples. Total RNA was extracted from the urine sediment by using TRIzol reagent, and complementary DNA was synthesized using TransPlex Complete Whole Transcriptome Amplification Kit (WTA2). Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level. The TTTY15-USP9Y score was calculated as 2(Ct(PSA)-Ct(TTTY15-USP9Y))× 1,000. RESULTS: The TTTY15-USP9Y score was statistically significantly higher in men with positive biopsy outcome than in men with negative biopsy outcome (P<0.001). The area under the curve was 0.828 for the TTTY15-USP9Y score in the entire patient cohort. The TTTY15-USP9Y score׳s cutoff of 90.28 provided the optimal balance between sensitivity (84.0%) and specificity (77.5%). The combination of PSA level and the TTTY15-USP9Y score significantly improved the diagnostic performance of PSA level (P = 0.001). The TTTY15-USP9Y score alone was superior to PSA level, percent free PSA, and PSA density (serum PSA/prostate volume) in the subgroup of clinical interest (PSA level: 4-10ng/ml, gray zone). Univariable and multivariable logistic analyses indicated that TTTY15-USP9Y score, PSA level, age, and prostate volume were independent predictors of PCa. Adding the TTTY15-USP9Y score in the clinical base model (PSA level, age, and prostate volume) could bring a higher net benefit and reduce more unnecessary biopsies in the defined range of interest (10%-40% threshold probability). CONCLUSION: In conclusion, our study explored the potential utility of measuring the TTTY15-USP9Y score in post-digital rectal examination urine samples to predict biopsy outcome and provided the basis for the utility of this novel gene fusion in multicenter and large cohort studies.
OBJECTIVE: In recent years, great effort has been made to explore new biomarkers for early detection of prostate cancer. Our previous study has demonstrated the high prevalence of TTTY15-USP9Y in prostate cancer samples from a Chinese population. Our aim was to evaluate the clinical utility of TTTY15-USP9Y in predicting the prostate biopsy outcome. MATERIALS AND METHODS: We retrospectively examined the expression of TTTY15-USP9Y in 226 qualified urine sediment samples. Total RNA was extracted from the urine sediment by using TRIzol reagent, and complementary DNA was synthesized using TransPlex Complete Whole Transcriptome Amplification Kit (WTA2). Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level. The TTTY15-USP9Y score was calculated as 2(Ct(PSA)-Ct(TTTY15-USP9Y))× 1,000. RESULTS: The TTTY15-USP9Y score was statistically significantly higher in men with positive biopsy outcome than in men with negative biopsy outcome (P<0.001). The area under the curve was 0.828 for the TTTY15-USP9Y score in the entire patient cohort. The TTTY15-USP9Y score׳s cutoff of 90.28 provided the optimal balance between sensitivity (84.0%) and specificity (77.5%). The combination of PSA level and the TTTY15-USP9Y score significantly improved the diagnostic performance of PSA level (P = 0.001). The TTTY15-USP9Y score alone was superior to PSA level, percent free PSA, and PSA density (serum PSA/prostate volume) in the subgroup of clinical interest (PSA level: 4-10ng/ml, gray zone). Univariable and multivariable logistic analyses indicated that TTTY15-USP9Y score, PSA level, age, and prostate volume were independent predictors of PCa. Adding the TTTY15-USP9Y score in the clinical base model (PSA level, age, and prostate volume) could bring a higher net benefit and reduce more unnecessary biopsies in the defined range of interest (10%-40% threshold probability). CONCLUSION: In conclusion, our study explored the potential utility of measuring the TTTY15-USP9Y score in post-digital rectal examination urine samples to predict biopsy outcome and provided the basis for the utility of this novel gene fusion in multicenter and large cohort studies.
Authors: Paolo Bossi; Marco Siano; Lisa Licitra; Loris De Cecco; Cristiana Bergamini; Maria Cossu Rocca; Andrea P Sponghini; Marco Giannoccaro; Luca Tonella; Alessandro Paoli; Edoardo Marchesi; Federica Perrone; Silvana Pilotti; Laura D Locati; Silvana Canevari Journal: Dis Markers Date: 2017-11-12 Impact factor: 3.434
Authors: Jason Glover; Tsz-Kwong Man; Donald A Barkauskas; David Hall; Tanya Tello; Mary Beth Sullivan; Richard Gorlick; Katherine Janeway; Holcombe Grier; Ching Lau; Jeffrey A Toretsky; Scott C Borinstein; Chand Khanna; Timothy M Fan Journal: PLoS One Date: 2017-07-21 Impact factor: 3.240